NCT00951665View on ClinicalTrials.gov

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

June 30, 2013

Conditions
Metastatic Breast Cancer
Interventions
DRUG

paclitaxel

Intravenous repeating dose

DRUG

pertuzumab [Perjeta]

Intravenous repeating dose

DRUG

trastuzumab emtansine [Kadcyla]

Intravenous escalating dose

DRUG

paclitaxel

Intravenous escalating dose

DRUG

trastuzumab emtansine [Kadcyla]

Intravenous repeating dose

Trial Locations (5)

10065

New York

48201

Detroit

80045

Aurora

94305-5456

Stanford

02115

Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY